# US 2026/0232810 A1 · Novel lipids and compositions for the delivery of therapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232810 A1
- Document ID: US20260232810A1
- Status: Published application
- Kind: A1
- Application number: 19/263,764
- Filed: 2025-07-09
- Published: 2026-08-13
- Earliest claimed: 2008-11-10
- Assignees: Arbutus Biopharma Corporation
- Applicants: Arbutus Biopharma Corporation
- Inventors: Muthiah Manoharan; Muthusamy Jayaraman; Kallanthottathil G. Rajeev; Laxman Eltepu; Steven Ansell; Jianxin Chen
- Web page: https://patentgrep.com/patent/US20260232810A1

## CPC

- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/20: containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/04: Immunostimulants
- C07C 229/08: the nitrogen atom of the amino group being further bound to hydrogen atoms
- C07C 229/30: the carbon skeleton being acyclic and unsaturated
- C07C 237/16: the carbon skeleton being acyclic and unsaturated
- C07C 251/38: to carbon atoms of a saturated carbon skeleton
- C07C 251/78: to carbon atoms of an unsaturated carbon skeleton
- C07C 271/12: to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 271/20: to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 323/25: the carbon skeleton being acyclic and saturated
- C07D 203/10: Radicals substituted by singly bound oxygen atoms
- C07D 317/28: Radicals substituted by nitrogen atoms (nitro radicals C07D317/16)
- C07D 317/44: ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D 317/46: condensed with one six-membered ring
- C07D 317/72: spiro-condensed with carbocyclic rings
- C07D 319/06: not condensed with other rings
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 491/056: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C07D 491/113: with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure wherein: R1 and R2 are each independently for each occurrence optionally substituted C10-C30 alkyl, optionally substituted C10-C30 alkenyl, optionally substituted C10-C30 alkynyl, optionally substituted C10-C30 acyl, or -linker-ligand; R3 is H, optionally substituted C1-C10 alkyl, optionally substituted C2-C10 alkenyl, optionally substituted C2-C10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω-(substituted)aminoalkyls, ω-phosphoalkyls, ω-thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; and E is C(O)O or OC(O).

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

A cationic lipid having the structure
or a salt thereof,
wherein
E is C(O)O or OC(O);
R1 and R2 are each independently C1-C10 alkyl and Rx is H;
R3 is di(alkyl)aminoalkyl substituted with one or more alkoxy, alkoxycarbonyl, and hydroxy, wherein alkoxy is optionally substituted with one or more alkyl and oxo; and
n is 0.

### Claim 27 (depends on 26)

The cationic lipid of claim 26, wherein E is OC(O).

### Claim 28 (depends on 26)

The cationic lipid of claim 26, wherein R3 is di(alkyl)aminoalkyl substituted with alkoxy and hydroxy, wherein alkoxy is substituted with alkyl and oxo.

### Claim 29 (depends on 27)

The cationic lipid of claim 27, wherein R3 is di(alkyl)aminoalkyl substituted with alkoxy and hydroxy, wherein alkoxy is substituted with alkyl and oxo.

### Claim 30 (depends on 26)

A lipid particle comprising a cationic lipid of claim 26 or a salt thereof.

### Claim 31 (depends on 30)

The lipid particle of claim 30, wherein the particle comprises about 40-60 mol % of the cationic lipid.

### Claim 32 (depends on 30)

The lipid particle of claim 30, wherein the cationic lipid has a pKa of about 4 to about 7.

### Claim 33 (depends on 30)

The lipid particle of claim 30, wherein the particle further comprises a neutral lipid and a lipid capable of reducing aggregation.

### Claim 34 (depends on 33)

The lipid particle of claim 33, wherein the neutral lipid is a phospholipid.

### Claim 35 (depends on 33)

The lipid particle of claim 33, wherein the lipid capable of reducing aggregation is a PEG-lipid.

### Claim 36 (depends on 33)

The lipid particle of claim 33, wherein the neutral lipid is a phospholipid and the lipid capable of reducing aggregation is a PEG-lipid.

### Claim 37 (depends on 33)

The lipid particle of claim 33, wherein the particle further comprises a sterol.

### Claim 38 (depends on 37)

The lipid particle of claim 37, wherein the sterol is cholesterol.

### Claim 39 (depends on 36)

The lipid particle of claim 36, wherein the particle further comprises a sterol.

### Claim 40 (depends on 39)

The lipid particle of claim 39, wherein the sterol is cholesterol.

### Claim 41 (depends on 31)

The lipid particle of claim 31, wherein the particle further comprises a neutral lipid and a lipid capable of reducing aggregation.

### Claim 42 (depends on 41)

The lipid particle of claim 41, wherein the neutral lipid is a phospholipid.

### Claim 43 (depends on 41)

The lipid particle of claim 41, wherein the lipid capable of reducing aggregation is a PEG-lipid.

### Claim 44 (depends on 41)

The lipid particle of claim 41, wherein the neutral lipid is a phospholipid and the lipid capable of reducing aggregation is a PEG-lipid.

### Claim 45 (depends on 41)

The lipid particle of claim 41, wherein the particle further comprises a sterol.

### Claim 46 (depends on 45)

The lipid particle of claim 45, wherein the sterol is cholesterol.

### Claim 47 (depends on 44)

The lipid particle of claim 44, wherein the particle further comprises a sterol.

### Claim 48 (depends on 47)

The lipid particle of claim 47, wherein the sterol is cholesterol.

### Claim 49 (depends on 37)

The lipid particle of claim 37, further comprising a therapeutic agent.

### Claim 50 (depends on 49)

The lipid particle of claim 49, wherein the therapeutic agent is a nucleic acid.

### Claim 51 (depends on 50)

The lipid particle of claim 50, wherein the nucleic acid is an mRNA.

### Claim 52 (depends on 39)

The lipid particle of claim 39, further comprising a therapeutic agent.

### Claim 53 (depends on 52)

The lipid particle of claim 52, wherein the therapeutic agent is a nucleic acid.

### Claim 54 (depends on 53)

The lipid particle of claim 53, wherein the nucleic acid is an mRNA.

### Claim 55 (depends on 45)

The lipid particle of claim 45, further comprising a therapeutic agent.

### Claim 56 (depends on 55)

The lipid particle of claim 55, wherein the therapeutic agent is a nucleic acid.

### Claim 57 (depends on 56)

The lipid particle of claim 56, wherein the nucleic acid is an mRNA.

### Claim 58 (depends on 47)

The lipid particle of claim 47, further comprising a therapeutic agent.

### Claim 59 (depends on 58)

The lipid particle of claim 58, wherein the therapeutic agent is a nucleic acid.

### Claim 60 (depends on 59)

The lipid particle of claim 59, wherein the nucleic acid is an mRNA.

### Claim 61 (depends on 29)

A lipid particle comprising a cationic lipid of claim 29 or a salt thereof.

### Claim 62 (depends on 61)

The lipid particle of claim 61, wherein the particle comprises about 40-60 mol % of the cationic lipid.

### Claim 63 (depends on 61)

The lipid particle of claim 61, wherein the cationic lipid has a pKa of about 4 to about 7.

### Claim 64 (depends on 61)

The lipid particle of claim 61, wherein the particle further comprises a neutral lipid and a lipid capable of reducing aggregation.

### Claim 65 (depends on 64)

The lipid particle of claim 64, wherein the neutral lipid is a phospholipid.

### Claim 66 (depends on 64)

The lipid particle of claim 64, wherein the lipid capable of reducing aggregation is a PEG-lipid.

### Claim 67 (depends on 64)

The lipid particle of claim 64, wherein the neutral lipid is a phospholipid and the lipid capable of reducing aggregation is a PEG-lipid.

### Claim 68 (depends on 64)

The lipid particle of claim 64, wherein the particle further comprises a sterol.

### Claim 69 (depends on 68)

The lipid particle of claim 68, wherein the sterol is cholesterol.

### Claim 70 (depends on 67)

The lipid particle of claim 67, wherein the particle further comprises a sterol.

### Claim 71 (depends on 70)

The lipid particle of claim 70, wherein the sterol is cholesterol.

### Claim 72 (depends on 62)

The lipid particle of claim 62, wherein the particle further comprises a neutral lipid and a lipid capable of reducing aggregation.

### Claim 73 (depends on 72)

The lipid particle of claim 72, wherein the neutral lipid is a phospholipid.

### Claim 74 (depends on 72)

The lipid particle of claim 72, wherein the lipid capable of reducing aggregation is a PEG-lipid.

### Claim 75 (depends on 72)

The lipid particle of claim 72, wherein the neutral lipid is a phospholipid and the lipid capable of reducing aggregation is a PEG-lipid.

### Claim 76 (depends on 72)

The lipid particle of claim 72, wherein the particle further comprises a sterol.

### Claim 77 (depends on 76)

The lipid particle of claim 76, wherein the sterol is cholesterol.

### Claim 78 (depends on 75)

The lipid particle of claim 75, wherein the particle further comprises a sterol.

### Claim 79 (depends on 78)

The lipid particle of claim 78, wherein the sterol is cholesterol.

### Claim 80 (depends on 68)

The lipid particle of claim 68, further comprising a therapeutic agent.

### Claim 81 (depends on 80)

The lipid particle of claim 80, wherein the therapeutic agent is a nucleic acid.

### Claim 82 (depends on 81)

The lipid particle of claim 81, wherein the nucleic acid is an mRNA.

### Claim 83 (depends on 70)

The lipid particle of claim 70, further comprising a therapeutic agent.

### Claim 84 (depends on 83)

The lipid particle of claim 83, wherein the therapeutic agent is a nucleic acid.

### Claim 85 (depends on 84)

The lipid particle of claim 84, wherein the nucleic acid is an mRNA.

### Claim 86 (depends on 76)

The lipid particle of claim 76, further comprising a therapeutic agent.

### Claim 87 (depends on 86)

The lipid particle of claim 86, wherein the therapeutic agent is a nucleic acid.

### Claim 88 (depends on 87)

The lipid particle of claim 87, wherein the nucleic acid is an mRNA.

### Claim 89 (depends on 78)

The lipid particle of claim 78, further comprising a therapeutic agent.

### Claim 90 (depends on 89)

The lipid particle of claim 89, wherein the therapeutic agent is a nucleic acid.

### Claim 91 (depends on 90)

The lipid particle of claim 90, wherein the nucleic acid is an mRNA.

### Claim 92 (depends on 49)

A pharmaceutical composition comprising a lipid particle of claim 49 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 93 (depends on 52)

A pharmaceutical composition comprising a lipid particle of claim 52 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 94 (depends on 55)

A pharmaceutical composition comprising a lipid particle of claim 55 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 95 (depends on 58)

A pharmaceutical composition comprising a lipid particle of claim 58 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 96 (depends on 80)

A pharmaceutical composition comprising a lipid particle of claim 80 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 97 (depends on 83)

A pharmaceutical composition comprising a lipid particle of claim 83 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 98 (depends on 86)

A pharmaceutical composition comprising a lipid particle of claim 86 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 99 (depends on 89)

A pharmaceutical composition comprising a lipid particle of claim 89 and a pharmaceutically acceptable excipient, carrier, or diluent.

### Claim 100 (depends on 49)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 49.

### Claim 101 (depends on 52)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 52.

### Claim 102 (depends on 55)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 55.

### Claim 103 (depends on 58)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 58.

### Claim 104 (depends on 80)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 80.

### Claim 105 (depends on 83)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 83.

### Claim 106 (depends on 86)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 86.

### Claim 107 (depends on 89)

A method of modulating the expression of a target gene in a cell, comprising providing to the cell the lipid particle of claim 89.

### Claim 108 (depends on 26)

The cationic lipid of claim 26, wherein E is C(O)O.

### Claim 109 (depends on 26)

The cationic lipid of claim 26, wherein R3 is di(alkyl)aminoalkyl substituted with alkoxycarbonyl and hydroxy.

### Claim 110 (depends on 108)

The cationic lipid of claim 108, wherein R3 is di(alkyl)aminoalkyl substituted with alkoxycarbonyl and hydroxy.

### Claim 111 (depends on 110)

A lipid particle comprising a cationic lipid of claim 110 or a salt thereof.

### Claim 112 (depends on 111)

The lipid particle of claim 111, wherein the particle comprises about 40-60 mol % of the cationic lipid.

### Claim 113 (depends on 111)

The lipid particle of claim 111, wherein the cationic lipid has a pKa of about 4 to about 7.

### Claim 114 (depends on 111)

The lipid particle of claim 111, wherein the particle further comprises a neutral lipid and a lipid capable of reducing aggregation.

### Claim 115 (depends on 114)

The lipid particle of claim 114, wherein the particle further comprises a sterol.

### Claim 116 (depends on 115)

The lipid particle of claim 115, further comprising a therapeutic agent.

### Claim 117 (depends on 116)

The lipid particle of claim 116, wherein the therapeutic agent is a nucleic acid.

### Claim 118 (depends on 117)

The lipid particle of claim 117, wherein the nucleic acid is an mRNA.
